An observational study in Gynaecological Oncology, sponsored by Assiut University. Not yet recruiting. Open to female participants. Per ClinicalTrials.gov, last updated 2025-11-18.
Sponsored by Assiut University · Observational
This retrospective cohort study investigates survival outcomes of gynecological oncology patients treated at Assiut University Hospital between 2022 and 2025, comparing them to international benchmarks and assessing factors affecting survival.
The study aims to evaluate overall survival (OS) and progression-free survival (PFS) of patients diagnosed with gynecological cancers (including ovarian, cervical, endometrial, vulvar, and vaginal cancers) and treated at Assiut University Hospital from January 1, 2022, to December 31, 2025. Using retrospective medical records and pathology reports, the study will analyze demographic, clinical, and treatment-related variables to identify factors influencing survival outcomes. Assiut University is a tertiary care center in a low-resource setting; thus, the study will also assess adherence to international oncology guidelines (e.g., ESMO, ASCO) and compare local survival rates with international standards. Statistical methods include Kaplan-Meier survival analysis and Cox proportional hazards modeling.
Assiut University is the lead sponsor of 4,901 studies on the registry; 2,098 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
All female patients diagnosed with gynecological cancers (including ovarian, cervical, endometrial, vulvar, and vaginal cancer) and treated at Assiut University Gynecological Oncology Department between January 1, 2022, and December 31, 2025, will be included. Patients of all ages and backgrounds are eligible. Exclusion criteria are non-gynecological cancers, metastatic cancers originating outside the gynecologic tract, incomplete medical records, or significant comorbidities that independently affect survival (e.g., advanced heart failure, severe liver or renal disease, or unrelated terminal illnesses).
- Patients diagnosed with gynecological cancers (ovarian, cervical, endometrial, vulvar, vaginal)
Patients treated at Assiut University Gynecological Oncology Department between January 1, 2022, and December 31, 2025
All age groups included
Exclusion Criteria:
- Patients with non-gynecological malignancies or metastatic cancers originating outside the gynecological tract
Patients with incomplete medical records (e.g., missing pathology reports or treatment details)
Patients with significant comorbidities independently affecting survival (e.g., advanced heart failure, severe liver or renal disease, terminal illnesses unrelated to cancer)
Overall Survival
Overall survival (OS) is defined as the duration of time from the date of cancer diagnosis or initiation of treatment until death from any cause. Patients will be censored at the date of last follow-up if alive at study end. This outcome will provide a direct estimate of survival rates among gynecological oncology patients treated at Assiut University Hospital.
Time frame: 4 years
No study locations are listed for this record.
This study is not yet recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assiut University